Switch theme
Sign up to access all valuation multiples
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
2021
n/a
Last FY Revenue n/a
Last FY EBITDA -$20.6M
$68.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Citius Oncology achieved revenue of n/a and an EBITDA of -$20.6M.
Citius Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Citius Oncology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$20.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | n/a | XXX | -$20.6M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$31.5M | XXX | -$21.1M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $3.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Citius Oncology's stock price is $1.
Citius Oncology has current market cap of $64.4M, and EV of $68.2M.
See Citius Oncology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $68.2M | $64.4M | XXX | XXX | XXX | XXX | $-0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Citius Oncology has market cap of $64.4M and EV of $68.2M.
Citius Oncology's trades at n/a EV/Revenue multiple, and -4.8x EV/EBITDA.
Equity research analysts estimate Citius Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Citius Oncology has a P/E ratio of -2.0x.
See valuation multiples for Citius Oncology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $64.4M | XXX | $64.4M | XXX | XXX | XXX |
| EV (current) | $68.2M | XXX | $68.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -4.8x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -3.1x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.0x | XXX | -2.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCitius Oncology's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Citius Oncology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Citius Oncology's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Citius Oncology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Citius Oncology acquired XXX companies to date.
Last acquisition by Citius Oncology was XXXXXXXX, XXXXX XXXXX XXXXXX . Citius Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Citius Oncology founded? | Citius Oncology was founded in 2021. |
| Where is Citius Oncology headquartered? | Citius Oncology is headquartered in United States of America. |
| Who is the CEO of Citius Oncology? | Citius Oncology's CEO is Mr. Leonard L. Mazur. |
| Is Citius Oncology publicy listed? | Yes, Citius Oncology is a public company listed on NAS. |
| What is the stock symbol of Citius Oncology? | Citius Oncology trades under CTOR ticker. |
| When did Citius Oncology go public? | Citius Oncology went public in 2024. |
| Who are competitors of Citius Oncology? | Similar companies to Citius Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Citius Oncology? | Citius Oncology's current market cap is $64.4M |
| Is Citius Oncology profitable? | Yes, Citius Oncology is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
